logo

For the Inventor, By the Inventor

Wokingham, United Kingdom

Jeremy Martin Davis

This inventor holds 19 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent, primarily in Kinase Inhibitors. Top assignees: Ucb Pharma, S.a., Celltech R&d Limited, Celltech Therapeutics Limited. Active years: 1999-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeremy Martin Davis. Retrieved from https://idiyas.com/inventor/jeremy-martin-davis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 63.2



Average Co-Inventor Count = 3.8

ph-index = 11

Forward Citations = 736(Granted Patents)


Location History:

  • Workingham, GB (2003 - 2007)
  • Wokingham, GB (1999 - 2010)
  • Berkshire, GB (2010 - 2012)
  • Slough Berkshire, GB (2013)

Company Filing History:

goldMedal8 out of 180 
 
Ucb Pharma, S.a.
 patents
silverMedal6 out of 68 
 
Celltech R&d Limited
 patents
bronzeMedal5 out of 81 
 
Celltech Therapeutics Limited
 patents

Years Active: 1999-2013

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Thieno-Pyridine Derivatives
Kinase Inhibitors
Bicyclic Heteroaromatic Compounds
Aminopyrimidine Derivatives
P38 Kinase Inhibitors
Fused Polycyclic Compounds
Protein Kinase Inhibitors
Oxopyridine Derivatives
Anilinopyrimidines
MEK Inhibitors
Aromatic Compounds
Tyrosine Kinase Inhibitors
19 patents (USPTO):Explore Patents
1. 8604051 - Thieno-pyridine derivatives as MEK inhibitors (2013-12-10),
2. 8394822 - Thieno-pyridine derivatives as MEK inhibitors (2013-03-12),
3. 8283359 - Thieno-pyridine derivatives as MEK inhibitors (2012-10-09),
4. 7795256 - Thieno-pyridinone derivatives as kinase inhibitors (2010-09-14),
5. 7763729 - Bicyclic heteroaromatic derivatives (2010-07-27),
6. 7592455 - Bicyclic heteroaromatic compounds as kinase inhibitors (2009-09-22),
7. 7521460 - Thienopyridone derivatives as kinase inhibitors (2009-04-21),
8. 7456286 - Bicyclic heteroaromatic compounds as kinase inhibitors (2008-11-25),
9. 7423047 - Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors (2008-09-09),
10. 7323464 - Pyridine and pyrimidine derivatives (2008-01-29),
11. 7176215 - Bicyclic oxopyridine and oxopyrimidine derivatives (2007-02-13),
12. 6600037 - 4,5-disubstituted-2-aminopyrimidines (2003-07-29),
13. 6599908 - Fused polycyclic 2-aminopyrimidine derivatives (2003-07-29),
14. 6579983 - 5-cyano-2-aminopyrimidine derivatives (2003-06-17),
15. 6235746 - Substituted 2-anilinopyrimidines useful as protein kinase inhibitors (2001-05-22),

Title: Jeremy Martin Davis - Innovative Inventor from Wokingham, GB

Introduction: Jeremy Martin Davis is a renowned inventor hailing from Wokingham, GB, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Jeremy Martin Davis holds several patents in the areas of technology, healthcare, and sustainable energy, showcasing his diverse range of expertise and interests.

Career Highlights: Throughout his illustrious career, Jeremy Martin Davis has been recognized for his ability to transform complex ideas into practical solutions. His inventions have significantly impacted industries such as robotics, biotechnology, and environmental conservation.

Collaborations: Jeremy Martin Davis has collaborated with leading research institutions, universities, and multinational companies to further develop and implement his inventions on a global scale. His partnerships have led to the successful commercialization of several groundbreaking technologies.

Conclusion: Jeremy Martin Davis continues to push the boundaries of innovation, inspiring the next generation of inventors with his creative vision and passion for creating a positive impact on society through his inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…